

Tasigna[®] (nilotinib) – First-time generic

- On May 27, 2025, [Apotex launched](#) an [AB-rated](#) generic version of Novartis' [Tasigna \(nilotinib\)](#) capsules.
 - Apotex was granted 180-days of generic exclusivity for its generic Tasigna.
- Tasigna is approved for the:
 - Treatment of adult and pediatric patients greater than or equal to 1 year of age with newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phase
 - Treatment of adult patients with chronic phase and accelerated phase Ph+ CML resistant or intolerant to prior therapy that included imatinib
 - Treatment of pediatric patients greater than or equal to 1 year of age with chronic phase and accelerated phase Ph+ CML with resistance or intolerance to prior tyrosine-kinase inhibitor (TKI) therapy.
- Tasigna carries a boxed warning for QT prolongation and sudden deaths.